U.S.'s Trovagene and UAE's Alliance Global (AGBL) sign a medical distribution agreement

22 February, 2017

Trovagene, Inc. (NASDAQ: TROV), (San Diego, CA), a developer of circulating tumor DNA (ctDNA) technologies, signed a distribution agreement with AGBL (Dubai, UAE) to bring Trovagene Liquid Biopsy tests to AGBL’s markets.

“Trovagene has innovative liquid biopsy solutions for cancer patients,” said Dr. Simona Maciotta, Product Manager at AGBL. “Their clinically, actionable, highly sensitive mutation assays will allow clinicians to make critical decisions about medication and prognosis more quickly, which can have a life-changing impact on patients’ lives.” 

-Ends-

About Trovagene
Headquartered in San Diego, California, Trovagene is leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in an effort to enable itself and others through the distribution of research use kits and systems, to detect and monitor ctDNA in urine and blood. The Company’s technology allows for detection and quantitation of oncogene mutations in cancer patients for improved disease management. Trovagene’s PCM technology is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property, including multiple issued patents and pending patent applications globally. For more information, please visit: https://www.trovagene.com/   

About AGBL 
AGBL is the largest biomedical gateway to the emerging markets of the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MEAA region. The group’s stated mission is to improve the lives of the region’s inhabitants through novel biomedical technologies and products. For more information, please visit: www.agbl.net